DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Forsta AP Fonden

Key Points

• Forsta AP Fonden increased its stake in DexCom, Inc. by 6.0%, owning 88,100 shares valued at approximately $6.02 million after acquiring an additional 5,000 shares in the first quarter.
• Institutional investors own around 97.75% of DexCom's stock, highlighting strong confidence and investment interest in the company.
• DexCom reported earnings of $0.48 per share for the most recent quarter, exceeding consensus estimates, with revenues of $1.16 billion, showing a 15.2% year-over-year increase.

Forsta AP Fonden grew its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,100 shares of the medical device company's stock after purchasing an additional 5,000 shares during the period. Forsta AP Fonden's holdings in DexCom were worth $6,016,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. National Bank of Canada FI increased its stake in DexCom by 139.6% during the 1st quarter. National Bank of Canada FI now owns 569,011 shares of the medical device company's stock worth $38,858,000 after buying an additional 331,528 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in DexCom by 8.7% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 988,778 shares of the medical device company's stock worth $67,524,000 after buying an additional 79,194 shares during the period. Headlands Technologies LLC increased its stake in DexCom by 293.5% during the 1st quarter. Headlands Technologies LLC now owns 24,587 shares of the medical device company's stock worth $1,679,000 after buying an additional 18,339 shares during the period. Monetta Financial Services Inc. acquired a new position in shares of DexCom in the first quarter worth about $683,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of DexCom by 5.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,987,656 shares of the medical device company's stock worth $204,027,000 after acquiring an additional 162,450 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

NASDAQ:DXCM traded up $0.03 during midday trading on Thursday, reaching $79.99. 1,736,890 shares of the company traded hands, compared to its average volume of 3,905,361. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The firm has a market capitalization of $31.37 billion, a price-to-earnings ratio of 55.55, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a fifty day moving average price of $83.28 and a 200 day moving average price of $80.19.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the firm posted $0.43 EPS. The business's revenue for the quarter was up 15.2% compared to the same quarter last year. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president owned 95,602 shares in the company, valued at $8,057,336.56. The trade was a 9.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,656 shares of company stock worth $2,412,191. 0.32% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent analyst reports. UBS Group boosted their price target on DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Truist Financial started coverage on DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 price objective on the stock. Oppenheimer lifted their price objective on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, July 31st. Citigroup restated a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Finally, William Blair raised shares of DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.